Participant characteristics at the time of plasma collection for protein measurement, Atherosclerosis Risk in Communities study
| Variable . | ARIC Visit 3 . | ARIC Visit 5 . |
|---|---|---|
| n = 8374 . | n = 3730 . | |
| Demographic variables | ||
| Age, years, (SD) | 59.98 (5.67) | 75.45 (5.05) |
| Female sex, no. (%) | 4541 (54.23) | 2141 (57.40) |
| Male sex, no. (%) | 3833 (45.77) | 1589 (42.60) |
| Black race, no. (%) | 1660 (19.82) | 655 (17.56) |
| White race, no. (%) | 6714 (80.18) | 3075 (82.44) |
| Clinical variables | ||
| Height, cm, (SD) | 168.18 (9.42) | 165.89 (9.56) |
| Weight, kg, (SD) | 80.70 (17.24) | 78.92 (17.24) |
| Systolic blood pressure, mmHg, (SD) | 124.47 (19.14) | 129.84 (17.93) |
| Diastolic blood pressure, mmHg, (SD) | 71.79 (10.42) | 65.84 (10.53) |
| Estimated glomerular filtration rate, mL/min/1.73 m2, (SD)a | 89.83 (14.14) | 72.05 (17.18) |
| Prevalent diabetes, no. (%)b | 1270 (15.17) | 1174 (31.47) |
| Prevalent myocardial infarction, no. (%)c | 513 (6.13) | 429 (11.5) |
| Prevalent heart failure, no. (%)d | 67 (0.80) | 431 (11.55) |
| Current smoker, no. (%) | 1504 (17.96) | 228 (6.11) |
| Antihypertensive medication use, no. (%)e | 3116 (37.59) | 2779 (74.50) |
| Prevalent AF, no. (%) | — | 229 (6.14) |
| Black, no. (%) | — | 18 (0.48) |
| White, no. (%) | — | 211 (5.66) |
| Incident AF, no. (%) | 1910 (22.81) | — |
| Black, no. (%) | 230 (2.75) | — |
| Incident AF within 5 years, no. (%) | 23 (0.27) | — |
| Incident AF after 5 years, no. (%) | 207 (2.47) | — |
| White, no. (%) | 1680 (20.06) | — |
| Incident AF within 5 years, no. (%) | 207 (2.47) | — |
| Incident AF after 5 years, no. (%) | 1473 (17.59) | — |
| Variable . | ARIC Visit 3 . | ARIC Visit 5 . |
|---|---|---|
| n = 8374 . | n = 3730 . | |
| Demographic variables | ||
| Age, years, (SD) | 59.98 (5.67) | 75.45 (5.05) |
| Female sex, no. (%) | 4541 (54.23) | 2141 (57.40) |
| Male sex, no. (%) | 3833 (45.77) | 1589 (42.60) |
| Black race, no. (%) | 1660 (19.82) | 655 (17.56) |
| White race, no. (%) | 6714 (80.18) | 3075 (82.44) |
| Clinical variables | ||
| Height, cm, (SD) | 168.18 (9.42) | 165.89 (9.56) |
| Weight, kg, (SD) | 80.70 (17.24) | 78.92 (17.24) |
| Systolic blood pressure, mmHg, (SD) | 124.47 (19.14) | 129.84 (17.93) |
| Diastolic blood pressure, mmHg, (SD) | 71.79 (10.42) | 65.84 (10.53) |
| Estimated glomerular filtration rate, mL/min/1.73 m2, (SD)a | 89.83 (14.14) | 72.05 (17.18) |
| Prevalent diabetes, no. (%)b | 1270 (15.17) | 1174 (31.47) |
| Prevalent myocardial infarction, no. (%)c | 513 (6.13) | 429 (11.5) |
| Prevalent heart failure, no. (%)d | 67 (0.80) | 431 (11.55) |
| Current smoker, no. (%) | 1504 (17.96) | 228 (6.11) |
| Antihypertensive medication use, no. (%)e | 3116 (37.59) | 2779 (74.50) |
| Prevalent AF, no. (%) | — | 229 (6.14) |
| Black, no. (%) | — | 18 (0.48) |
| White, no. (%) | — | 211 (5.66) |
| Incident AF, no. (%) | 1910 (22.81) | — |
| Black, no. (%) | 230 (2.75) | — |
| Incident AF within 5 years, no. (%) | 23 (0.27) | — |
| Incident AF after 5 years, no. (%) | 207 (2.47) | — |
| White, no. (%) | 1680 (20.06) | — |
| Incident AF within 5 years, no. (%) | 207 (2.47) | — |
| Incident AF after 5 years, no. (%) | 1473 (17.59) | — |
aEstimated glomerular filtration rate was calculated as mL/min/1.73 m2 using the CKD Epidemiology Collaboration equation containing plasma creatinine and cystatin C measurements.
bDiabetes was defined as having a fasting glucose > 126 mg/dL, a non-fasting glucose > 200 mg/dL, treatment for diabetes mellitus, or a self-reported physician diagnosis of diabetes.
cMyocardial infarction was defined as a history of adjudicated myocardial infarction or coronary revascularization procedure.
dHeart failure was adjudicated in ARIC by self-reported heart failure medication use within the past two weeks, or ICD-9 code 428.x or ICD-10 code I50 from hospitalization records.
eAntihypertensive medications included all medications indicated for hypertension: diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonist, adrenergic receptor antagonists, aldosterone receptor antagonists, and alpha-2 adrenergic receptor agonists.
Participant characteristics at the time of plasma collection for protein measurement, Atherosclerosis Risk in Communities study
| Variable . | ARIC Visit 3 . | ARIC Visit 5 . |
|---|---|---|
| n = 8374 . | n = 3730 . | |
| Demographic variables | ||
| Age, years, (SD) | 59.98 (5.67) | 75.45 (5.05) |
| Female sex, no. (%) | 4541 (54.23) | 2141 (57.40) |
| Male sex, no. (%) | 3833 (45.77) | 1589 (42.60) |
| Black race, no. (%) | 1660 (19.82) | 655 (17.56) |
| White race, no. (%) | 6714 (80.18) | 3075 (82.44) |
| Clinical variables | ||
| Height, cm, (SD) | 168.18 (9.42) | 165.89 (9.56) |
| Weight, kg, (SD) | 80.70 (17.24) | 78.92 (17.24) |
| Systolic blood pressure, mmHg, (SD) | 124.47 (19.14) | 129.84 (17.93) |
| Diastolic blood pressure, mmHg, (SD) | 71.79 (10.42) | 65.84 (10.53) |
| Estimated glomerular filtration rate, mL/min/1.73 m2, (SD)a | 89.83 (14.14) | 72.05 (17.18) |
| Prevalent diabetes, no. (%)b | 1270 (15.17) | 1174 (31.47) |
| Prevalent myocardial infarction, no. (%)c | 513 (6.13) | 429 (11.5) |
| Prevalent heart failure, no. (%)d | 67 (0.80) | 431 (11.55) |
| Current smoker, no. (%) | 1504 (17.96) | 228 (6.11) |
| Antihypertensive medication use, no. (%)e | 3116 (37.59) | 2779 (74.50) |
| Prevalent AF, no. (%) | — | 229 (6.14) |
| Black, no. (%) | — | 18 (0.48) |
| White, no. (%) | — | 211 (5.66) |
| Incident AF, no. (%) | 1910 (22.81) | — |
| Black, no. (%) | 230 (2.75) | — |
| Incident AF within 5 years, no. (%) | 23 (0.27) | — |
| Incident AF after 5 years, no. (%) | 207 (2.47) | — |
| White, no. (%) | 1680 (20.06) | — |
| Incident AF within 5 years, no. (%) | 207 (2.47) | — |
| Incident AF after 5 years, no. (%) | 1473 (17.59) | — |
| Variable . | ARIC Visit 3 . | ARIC Visit 5 . |
|---|---|---|
| n = 8374 . | n = 3730 . | |
| Demographic variables | ||
| Age, years, (SD) | 59.98 (5.67) | 75.45 (5.05) |
| Female sex, no. (%) | 4541 (54.23) | 2141 (57.40) |
| Male sex, no. (%) | 3833 (45.77) | 1589 (42.60) |
| Black race, no. (%) | 1660 (19.82) | 655 (17.56) |
| White race, no. (%) | 6714 (80.18) | 3075 (82.44) |
| Clinical variables | ||
| Height, cm, (SD) | 168.18 (9.42) | 165.89 (9.56) |
| Weight, kg, (SD) | 80.70 (17.24) | 78.92 (17.24) |
| Systolic blood pressure, mmHg, (SD) | 124.47 (19.14) | 129.84 (17.93) |
| Diastolic blood pressure, mmHg, (SD) | 71.79 (10.42) | 65.84 (10.53) |
| Estimated glomerular filtration rate, mL/min/1.73 m2, (SD)a | 89.83 (14.14) | 72.05 (17.18) |
| Prevalent diabetes, no. (%)b | 1270 (15.17) | 1174 (31.47) |
| Prevalent myocardial infarction, no. (%)c | 513 (6.13) | 429 (11.5) |
| Prevalent heart failure, no. (%)d | 67 (0.80) | 431 (11.55) |
| Current smoker, no. (%) | 1504 (17.96) | 228 (6.11) |
| Antihypertensive medication use, no. (%)e | 3116 (37.59) | 2779 (74.50) |
| Prevalent AF, no. (%) | — | 229 (6.14) |
| Black, no. (%) | — | 18 (0.48) |
| White, no. (%) | — | 211 (5.66) |
| Incident AF, no. (%) | 1910 (22.81) | — |
| Black, no. (%) | 230 (2.75) | — |
| Incident AF within 5 years, no. (%) | 23 (0.27) | — |
| Incident AF after 5 years, no. (%) | 207 (2.47) | — |
| White, no. (%) | 1680 (20.06) | — |
| Incident AF within 5 years, no. (%) | 207 (2.47) | — |
| Incident AF after 5 years, no. (%) | 1473 (17.59) | — |
aEstimated glomerular filtration rate was calculated as mL/min/1.73 m2 using the CKD Epidemiology Collaboration equation containing plasma creatinine and cystatin C measurements.
bDiabetes was defined as having a fasting glucose > 126 mg/dL, a non-fasting glucose > 200 mg/dL, treatment for diabetes mellitus, or a self-reported physician diagnosis of diabetes.
cMyocardial infarction was defined as a history of adjudicated myocardial infarction or coronary revascularization procedure.
dHeart failure was adjudicated in ARIC by self-reported heart failure medication use within the past two weeks, or ICD-9 code 428.x or ICD-10 code I50 from hospitalization records.
eAntihypertensive medications included all medications indicated for hypertension: diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonist, adrenergic receptor antagonists, aldosterone receptor antagonists, and alpha-2 adrenergic receptor agonists.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
